The loss of the interim report exceeded 200 million | Qianshan Pharmaceutical Machinery was reported by two directors in the semi-annual report
On August 31, the medical network, on the evening of August 29, Qianshan Pharmaceutical Co., Ltd. even announced 8 announcements, which disclosed that the company’s interim report had a loss of more than 200 million yuan. The company’s semi-annual report was rejected by one director, and two directors voted against it. Tickets and company stocks have a risk of suspension of listing risk.
According to the semi-annual report disclosed by Qianshan Pharmaceutical Machinery, the company's total operating income during the reporting period was approximately RMB 123 million, down 32.99% year-on-year; the corresponding net profit attributable to the current period was approximately -2.08 billion yuan, down 70.03% year-on-year. Among them, Qianshan Pharmaceutical also predicted the company's performance from January to September this year. It is estimated that the net profit loss attributable to shareholders of listed companies from January to September 2018 will range from 720 million yuan to 725 million yuan. The main reason for the performance loss is that it is affected by factors such as the company's debt crisis and asset restrictions. The company's production and operation progress has slowed down, and operating income has decreased. The company's loan interest has increased significantly year-on-year; medicine The original shareholders of 2017 Baotou Technology Co., Ltd.'s 2017 annual performance compensation of 388 million yuan for the full provision for impairment.
However, the semi-annual report was rejected by a director and two directors voted against it. On the evening of the same day, the resolution of the fifth meeting of the sixth board of directors disclosed by Qianshan Pharmaceutical Machinery revealed that the company’s semi-annual report was rejected by the director Jin Yiping. Ticket, Jin Yiping said, 'Asset impairment losses have a greater impact on the profit of the 2018 semi-annual statement, and the appropriate estimate of the contingent liabilities arising from the asset impairment losses and external guarantees in the 2018 semi-annual report cannot be determined, although The management explained the asset impairment losses and contingent issues, but still can not eliminate doubts.
In addition, director Yang Chunping and Shi Qinghui voted against it. Regarding the reasons for the vote, Yang Chunping said, 'The company is currently facing a debt crisis, operating difficulties, and there is a risk of suspension of listing of company shares. The interests of all shareholders of the company, especially small and medium shareholders, are affected. Loss, employee wages and benefits can not be paid on time, among which the important reasons include the illegal use of funds and performance compensation can not be recovered on time. In the proposal, how to supervise the repayment of the company funds occupied by the related parties and the original shareholders of Lok Fu Land to compensate the company's profits according to the agreement. The relevant measures are not specific. The early results of the supervision and repayment are not effective, and the pertinence is not strong. It is difficult to ensure that the company recovers these funds in time, and it is difficult to guarantee the interests of the company's shareholders, especially the small and medium shareholders.
Shi Qinghui said that in the semi-annual report of the company, 'the risks and countermeasures faced by the company', and the 'penalty and rectification situation', the company's management did not formulate concrete and feasible measures to solve the problem. In particular, the illegal external guarantees Risks, 'the risk of non-operating capital occupied by related parties' and 'risk of recovery of performance compensation' are three core risks, lack of specific solutions.
On the evening of August 29, Qianshan Pharmaceuticals also disclosed two notices about the risk of suspension of listing of the company's stock. According to the Shenzhen Stock Exchange. Start a business Section 13.1.1 (3) of the Board Listing Rules The financial accounting report of the most recent fiscal year shows that the audited net assets at the end of the year are negative, and the Shenzhen Stock Exchange may decide to suspend its stock listing. The newspaper expects that the net assets will be negative as of September 30, 2018. The company has a negative risk of net assets attributable to shareholders of the listed company at the end of 2018 after auditing. Qianshan Pharmaceutical said that if the company audited the 2018 financial accounting report It shows that the net assets at the end of 2018 are negative, and the Shenzhen Stock Exchange may suspend the listing of the company's stock.
In addition, Qianshan Pharmaceuticals also disclosed a risk warning announcement about the possibility that the company's shares may be suspended from listing if it is negative or unable to express an audit opinion. It is reported that Qianshan Pharmaceutical Machinery's 2017 financial report was issued by Ruihua Certified Public Accountants. The audit report, and as of June 30, 2018, the situation that led to the audit opinion has not been eliminated. Qianshan Pharmaceutical Machinery said that according to Article 13.1.1 (5) of the Shenzhen Stock Exchange GEM Listing Rules The financial accounting reports of the two most recent fiscal years have been issued by the CPA as negative or unable to express an opinion, and the Shenzhen Stock Exchange may decide to suspend the listing of its shares. If the company's 2018 financial accounting report continues to be issued, it is either negative or unrepresentable. Opinion's audit opinion, Shenzhen Stock Exchange may suspend the company's stock listing.
